Chimerism induction in vascularized bone marrow transplants augmented with bone marrow cells
Chimerism induction in vascularized bone marrow transplants augmented with bone marrow cells
复制标题
DOI：
10.1002/micr.20330
复制
发表时间：
2007-01-01
期刊：
影响因子：
2.1
通讯作者：
Siemionow, Maria
中科院分区：
文献类型：
--
作者：
Arslan, Emrah;Klimczak, Aleksandra;Siemionow, Maria
目前，同种异体复合组织移植物(CTA)已被临床所接受，但仍需要长期的免疫抑制来维持移植物的存活。供者特异性嵌合体的存在可能会诱导耐受。36例同种异体带血管骨髓移植(VBMT)患者在短期应用α-β-TCRmAb联合环孢素A治疗的基础上，跨越MHC屏障，观察VBMT和VBMT联合供者骨髓移植(BMT)诱导嵌合体的效果。流式细胞仪分析表明，供体BMT支持的VBMT与体内VBMT相比，嵌合体增强和维持，体外耐受性测试显示供体皮肤移植物存活时间延长达35天，MLR检测反应性中等，提示仅诱导耐受。无慢性免疫抑制的血管化骨移植提供了大量的骨髓细胞来源，导致了稳定的供者特异性嵌合体的发展。(C)2007年Wiley-Liss，Inc.
Composite tissue allografts (CTAs) are currently accepted in the clinic; however, long-term immunosuppression is still needed for allograft survival. The presence of donor-specific chimerism may induce tolerance. Thirty-six vascularized bone marrow transplantation (VBMT) allotransplantation were performed across MHC barrier under short-term protocol of 7-day alpha beta-TCRmAb and Cyclosporin A therapy to determine the efficacy of VBMT alone and VBMT augmented with donor bone marrow transplantation (BMT) in chimerism induction. Flow cytometry analysis revealed that VBMT supported with donor BMT directly into the bone resulted in chimerism augmentation and maintenance compared to VBMT In vivo and in vitro tolerance testing showed prolonged survival of donor skin graft up to 35 days and moderate reactivity in MLR assay that suggests only tolerance induction. Transplantation of vascularized bone without chronic immunosuppression provides a substantial source of bone marrow cells, leading to the development of stable donor-specific chimerism. (c) 2007 Wiley-Liss, Inc.